Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Study shows physicians reluctant to use finasteride for prostate cancer

Study shows physicians reluctant to use finasteride for prostate cancer

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Breath test to detect cancer: Study

Breath test to detect cancer: Study

Theragenics reports consolidated revenue of $20.8M for second-quarter 2010

Theragenics reports consolidated revenue of $20.8M for second-quarter 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Synta second-quarter net loss increases to $9.1 million

Synta second-quarter net loss increases to $9.1 million

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Scientists discover role of Mnk enzyme in prostate cancer development

Scientists discover role of Mnk enzyme in prostate cancer development

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis second-quarter pro forma net operating loss increases to $15.5 million

Progenics second-quarter total revenue decreases to $2.3 million

Progenics second-quarter total revenue decreases to $2.3 million

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

GTx second-quarter net loss increases to $12.9 million

GTx second-quarter net loss increases to $12.9 million

ESMO Congress provides forum for presentation of new research on treatment of cancer

ESMO Congress provides forum for presentation of new research on treatment of cancer

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

Surgery offers high survival rate for prostate cancer patients: Study

Surgery offers high survival rate for prostate cancer patients: Study

OncoGenex reports net income in second-quarter 2010 against loss last year

OncoGenex reports net income in second-quarter 2010 against loss last year

BCF publishes two new patient publications

BCF publishes two new patient publications

New laser technology for robotic prostate cancer surgery

New laser technology for robotic prostate cancer surgery

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.